

Kenneth L Marek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4405464/publications.pdf>

Version: 2024-02-01

129
papers

18,053
citations

26630

56
h-index

14759

127
g-index

133
all docs

133
docs citations

133
times ranked

14803
citing authors

#	ARTICLE	IF	CITATIONS
1	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	3.9	4,389
2	Levodopa and the Progression of Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2498-2508.	27.0	1,649
3	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011, 95, 629-635.	5.7	1,278
4	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	3.9	1,033
5	Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. <i>New England Journal of Medicine</i> , 1992, 327, 1541-1548.	27.0	569
6	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	3.9	379
7	Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders. <i>Science</i> , 2003, 302, 830-834.	12.6	362
8	The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	3.7	330
9	Association of Cerebrospinal Fluid β -Amyloid 1-42, T-tau, P-tau ₁₈₁ , and α -Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 1277-87.	9.0	318
10	Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 716.	4.5	295
11	The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. <i>Lancet Neurology</i> , The, 2008, 7, 417-424.	10.2	234
12	Role of DATASPECT in the diagnostic work up of Parkinsonism. <i>Movement Disorders</i> , 2007, 22, 1229-1238.	3.9	206
13	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016, 131, 935-949.	7.7	190
14	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	9.0	179
15	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology</i> , The, 2015, 14, 1002-1009.	10.2	179
16	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. <i>Lancet Neurology</i> , The, 2013, 12, 747-755.	10.2	175
17	Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. <i>Brain</i> , 2015, 138, 2964-2973.	7.6	164
18	Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome study. <i>Movement Disorders</i> , 2012, 27, 406-412.	3.9	162

#	ARTICLE	IF	CITATIONS
19	(123I) β -CIT and Single-Photon Emission Computed Tomographic Imaging vs Clinical Evaluation in Parkinsonian Syndrome. <i>Archives of Neurology</i> , 2004, 61, 1224-9.	4.5	160
20	[¹²³ I] β -CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2001, 16, 1023-1032.	3.9	159
21	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014, 82, 1791-1797.	1.1	147
22	Assessment of ¹⁸ F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	9.0	145
23	Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 435-457.	2.6	142
24	Imaging prodromal Parkinson disease. <i>Neurology</i> , 2014, 83, 1739-1746.	1.1	138
25	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018, 33, 771-782.	3.9	136
26	How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 62-67.	2.2	133
27	Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [¹²³ I] β -CIT. <i>Movement Disorders</i> , 1999, 14, 436-442.	3.9	131
28	Conversion to Parkinson Disease in the PARS HypoSMic and Dopamine Transporter "Deficit Prodromal Cohort. <i>JAMA Neurology</i> , 2017, 74, 933.	9.0	131
29	Finding useful biomarkers for Parkinson's disease. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	125
30	Tau PET imaging with ¹⁸ F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 911-919.	5.0	122
31	Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. <i>Neurology</i> , 2017, 89, 1959-1969.	1.1	121
32	Plasma apolipoprotein A1 as a biomarker for Parkinson disease. <i>Annals of Neurology</i> , 2013, 74, 119-127.	5.3	116
33	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1392-1397.	3.9	115
34	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	3.9	114
35	The Effect of the COVID-19 Pandemic on People with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1365-1377.	2.8	114
36	Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies. <i>Movement Disorders</i> , 2012, 27, 656-665.	3.9	113

#	ARTICLE	IF	CITATIONS
37	Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. <i>Movement Disorders</i> , 2004, 19, 916-923.	3.9	111
38	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 1999-2008.	3.9	104
39	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	10.2	94
40	The Natural History of the Syndrome of Primary Progressive Freezing Gait. <i>Archives of Neurology</i> , 2002, 59, 1778.	4.5	93
41	Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2011, 21, 234-246.	3.9	89
42	Longitudinal analyses of cerebrospinal fluid α -synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1354-1364.	3.9	89
43	Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 78-88.	1.9	85
44	Can we image premotor Parkinson disease?. <i>Neurology</i> , 2009, 72, S21-6.	1.1	84
45	[¹⁸ F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2077-2089.	6.4	84
46	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	10.2	82
47	The Phosphodiesterase 10 Positron Emission Tomography Tracer, [¹⁸ F]MNI-659, as a Novel Biomarker for Early Huntington Disease. <i>JAMA Neurology</i> , 2014, 71, 1520.	9.0	80
48	Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. <i>Brain</i> , 2019, 142, 3565-3579.	7.6	80
49	Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. <i>Movement Disorders</i> , 2015, 30, 1371-1381.	3.9	78
50	Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. <i>Movement Disorders</i> , 2016, 31, 86-94.	3.9	78
51	Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 653-662.	1.9	78
52	Association between α -synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. <i>Brain</i> , 2015, 138, 2659-2671.	7.6	69
53	Change in PDE10 across early Huntington disease assessed by [¹⁸ F]MNI-659 and PET imaging. <i>Neurology</i> , 2016, 86, 748-754.	1.1	65
54	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2017, 14, 164.	7.2	64

#	ARTICLE	IF	CITATIONS
55	Concordance for Parkinson's disease in twins: A 20-year update. <i>Annals of Neurology</i> , 2019, 85, 600-605.	5.3	64
56	In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: ¹⁸ F-MNI-659 and ¹⁸ F-MNI-654. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1297-1304.	5.0	61
57	Age dependence of brain β -amyloid deposition in Down syndrome. <i>Neurology</i> , 2015, 84, 500-507.	1.1	60
58	Kinetic Modeling of the Tau PET Tracer ¹⁸ F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1124-1131.	5.0	60
59	Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. <i>Journal of Nuclear Medicine</i> , 2018, 59, 937-943.	5.0	55
60	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020, 88, 574-587.	5.3	55
61	Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients. <i>Journal of Nuclear Medicine</i> , 2007, 48, 857-864.	5.0	54
62	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 1885-1892.	3.9	52
63	Characterization in Humans of ¹⁸ F-MNI-444, a PET Radiotracer for Brain Adenosine 2A Receptors. <i>Journal of Nuclear Medicine</i> , 2015, 56, 586-591.	5.0	49
64	Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers. <i>Molecular Imaging and Biology</i> , 2019, 21, 509-518.	2.6	49
65	A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. <i>Movement Disorders</i> , 2009, 24, 2081-2090.	3.9	48
66	The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies. <i>Movement Disorders</i> , 2017, 32, 726-738.	3.9	48
67	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020, 35, 833-844.	3.9	48
68	Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2249-2255.	3.9	47
69	Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: A β -CIT imaging study. <i>Neurobiology of Disease</i> , 2010, 38, 219-225.	4.4	46
70	Serum urate and probability of dopaminergic deficit in early Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1864-1868.	3.9	43
71	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	3.9	43
72	Plasma ¹²⁵ I-EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 346-355.	3.7	41

#	ARTICLE	IF	CITATIONS
73	Ergot alkaloids: Interaction with presynaptic dopamine receptors in the neostriatum and olfactory tubercles. <i>European Journal of Pharmacology</i> , 1980, 62, 137-146.	3.5	40
74	<i>Movement</i> Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013, 28, 1980-1986.	3.9	39
75	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1640-1645.	3.9	39
76	Tissue-Specific Regulation of Peptidyl-Glycine Î±-Amidating Monooxygenase Expression*. <i>Endocrinology</i> , 1989, 125, 2279-2288.	2.8	38
77	Rationale for delayedâ€start study of pramipexole in Parkinson's disease: The PROUD study. <i>Movement Disorders</i> , 2010, 25, 1627-1632.	3.9	38
78	Dopamine transporter imaging predicts clinicallyâ€defined <i>Î±</i>â€synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 201-212.	3.7	37
79	Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. <i>Clinical and Translational Science</i> , 2018, 11, 63-70.	3.1	36
80	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922.	6.4	36
81	Biosynthesis, Development, and Regulation of Neuropeptide Y in Superior Cervical Ganglion Culture. <i>Journal of Neurochemistry</i> , 1989, 52, 1807-1816.	3.9	35
82	Striatal dopamine transporters correlate with simple reaction time in elderly subjects. <i>Neurobiology of Aging</i> , 2008, 29, 1237-1246.	3.1	35
83	Biomarkers for Parkinson's disease: Tools to assess Parkinson's disease onset and progression. <i>Annals of Neurology</i> , 2008, 64, S111-S121.	5.3	35
84	Preclinical properties and human <i>in vivo</i> assessment of¹²³I-ABC577 as a novel SPECT agent for imaging amyloid-Î². <i>Brain</i> , 2016, 139, 193-203.	7.6	32
85	Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. <i>Alzheimer's and Dementia</i> , 2017, 13, 1117-1124.	0.8	31
86	Displacement of Serotonin and Dopamine Transporters by Venlafaxine Extended Release Capsule at Steady State. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 71-75.	1.4	30
87	Cerebrospinal fluid biomarkers and clinical features in leucineâ€rich repeat kinase 2 (<i>LRRK2</i>) mutation carriers. <i>Movement Disorders</i> , 2016, 31, 906-914.	3.9	29
88	Predictors of time to initiation of symptomatic therapy in early Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 482-494.	3.7	29
89	Plasma Î±-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. <i>Neurobiology of Disease</i> , 2018, 116, 53-59.	4.4	29
90	The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 553-563.	2.8	29

#	ARTICLE	IF	CITATIONS
91	Imaging the dopamine system to assess disease-modifying drugs. <i>Neurology</i> , 2003, 61, S43-8.	1.1	29
92	Dopamine agonists and Parkinson's disease progression: What can we learn from neuroimaging studies. <i>Annals of Neurology</i> , 2003, 53, S160-S169.	5.3	28
93	Neuroimaging Over the Course of Parkinson's Disease: From Early Detection of the At-Risk Patient to Improving Pharmacotherapy of Later-Stage Disease. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 406-414.	4.6	25
94	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease 1. <i>Journal of Parkinson's Disease</i> , 2015, 5, 581-594.	2.8	25
95	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. <i>Journal of Parkinson's Disease</i> , 2020, 10, 665-675.	2.8	25
96	Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of ¹⁸ F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2020, 61, 920-927.	5.0	24
97	Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. <i>Biological Psychiatry</i> , 1995, 38, 498-505.	1.3	23
98	Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-Up. <i>Movement Disorders</i> , 2020, 35, 1550-1557.	3.9	23
99	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	3.7	23
100	Clinical utility of DaTscan imaging in the evaluation of patients with parkinsonism: a US perspective. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 219-225.	2.8	22
101	Hemi-parkinsonism due to a midbrain arteriovenous malformation: dopamine transporter imaging. <i>Movement Disorders</i> , 2001, 16, 350-353.	3.9	21
102	Neuroimaging trials of Parkinson's disease progression. <i>Journal of Neurology</i> , 2004, 251, vii9-vii13.	3.6	20
103	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011, 26, 608-613.	3.9	20
104	Kinetic Modeling, Test-Retest, and Dosimetry of ¹²³ I-MNI-420 in Humans. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1760-1767.	5.0	18
105	Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. <i>Movement Disorders</i> , 2017, 32, 1636-1640.	3.9	18
106	Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Future. <i>Annals of the New York Academy of Sciences</i> , 1993, 695, 258-266.	3.8	17
107	Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using ¹²³ I-Hoflupane Injection (DaTscan) Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1288-1296.	5.0	17
108	Novel recruitment strategy to enrich for LRRK2 mutation carriers. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 404-412.	1.2	16

#	ARTICLE	IF	CITATIONS
109	Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. <i>Journal of Parkinson's Disease</i> , 2019, 9, 665-679.	2.8	15
110	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	2.2	15
111	Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease. <i>Clinical and Translational Science</i> , 2019, 12, 240-246.	3.1	15
112	Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person. <i>Journal of Parkinson's Disease</i> , 2020, 10, 677-691.	2.8	15
113	A practical approach to remote longitudinal follow-up of Parkinson's disease: The FOUND study. <i>Movement Disorders</i> , 2014, 29, 743-749.	3.9	14
114	Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 553-562.	4.7	13
115	A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0178982.	2.5	11
116	Traditional neuropsychological correlates and reliability of the Automated Neuropsychological Assessment Metrics-4 battery for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 864-870.	2.2	9
117	¹²³ I-β-CIT SPECT [(123) I-β-CIT (3-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography)] Imaging in a p.A53T L ^{166G} synuclein Parkinson's disease cohort versus Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1734-1739.	3.9	9
118	Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1783-1793.	2.8	7
119	Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 632-638.	1.6	7
120	The Role of the Core Imaging Laboratory in Multicenter Trials. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 338-346.	4.6	6
121	Differential regulation of neuropeptide Y and catecholamine production in superior cervical ganglion cultures. <i>Molecular and Cellular Neurosciences</i> , 1990, 1, 262-269.	2.2	3
122	Impact of Disclosure of Individual Imaging Results in a Multi-Center Parkinson Clinical Trial. <i>Journal of Parkinson's Disease</i> , 2014, 4, 629-638.	2.8	2
123	Unilateral Transplantation of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Patients With Parkinson's Disease. <i>Obstetrical and Gynecological Survey</i> , 1993, 48, 413-415.	0.4	1
124	Supplement neuroimaging movement disorders. <i>Movement Disorders</i> , 2009, 24, S655.	3.9	1
125	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 53-58.	1.5	1
126	Prospects for Slowing the Progression of Parkinson's Disease. , 2005, , 141-iii.		0

#	ARTICLE	IF	CITATIONS
127	Imaging of Dopamine Transporters: Biomarker for Progression in Parkinson's Disease. <i>CNS Neuroscience & Therapeutics</i> , 2006, 5, 19-19.	4.0	0
128	Reply: Unusual DAT scan results. <i>Movement Disorders</i> , 2013, 28, 847-847.	3.9	0
129	Observations on a 2-Step Approach to Screening for Parkinson Disease—Reply. <i>JAMA Neurology</i> , 2017, 74, 1506.	9.0	0